๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Guangzhou 38 Shanghai 34 Beijing 24 Chengdu 13 Wuhan 11
Narrow the registerReset
Recruitment status
Phase
Site location
Guangzhou38 Shanghai34 Beijing24 Chengdu13 Wuhan11
All 49 locations
Target enrolment
to

Trials with a site in Beijing

24 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
TROP2 NMR Concordance Study
NCT07624318Lung Cancer
AstraZeneca
Observational
3,400
Beijing, Guangzhou, Shanghai
2026-08-13
Recruiting
68Ga-SorB PET/CT Imaging in Patients With Solid Tumors
NCT07760012Melanoma (Skin Cancer), Hepatocellular Carcinoma, Lung Cancer, Breast Cancer
Peking University Third Hospital
Not applicable
50
Beijing
2026-07-24
Recruiting
Real-World Outcomes of Resected EGFR-Mutated NSCLC Patients Treated With Adjuvant EGFR-TKI in China
NCT07593248Lung Cancer
AstraZeneca
Observational
2,000
Beijing, Chengdu, Fuzhou, Guangzhou, Nanchang, Shanghai, Shenyang, Shijiazhuang
2026-06-22
Not yet open
5T4 Targeting Nanobody Probe for PET Imaging in Solid Tumors
NCT07589101Lung Cancer, Breast Cancer
Peking University Cancer Hospital & Institute
Not applicable
20
Beijing
2026-06-01
Recruiting
Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study
NCT07295821Lung Cancer
AstraZeneca
Phase 2
60
Beijing, Changchun, Changsha, Chengdu, Foshan, Fuzhou, Guangzhou, Harbin
2026-04-01
Recruiting
A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors
NCT07354711Lung Cancer, Stomach Cancer
3H Pharmaceuticals Co., Ltd.
Phase 1/2
170
Beijing
2026-01-04
By invitation
Spontaneous Breathing Mode: A Risk for Hypoxemia During OLV?
NCT07494006Lung Cancer, OLV, Hypoxemia During Surgery
Peking University People's Hospital
Observational
44
Beijing
2025-07-15
Recruiting
Spatially Fractionated Radiotherapy Combined With Immunotherapy for Advanced Solid Tumors
NCT07058948Solid Cancers, Radiotherapy, Immune Checkpoint Inhibitor, Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2
30
Beijing, Cangzhou, Tianjin
2025-07-01
Recruiting
The Regression Pattern of Primary Lesions in Lung Cancer After Definitive Radiotherapy
NCT06692972Lung Cancer
China-Japan Friendship Hospital
Observational
500
Beijing, Wuhan
2024-12-25
Active, closed
A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)
NCT06698042Lung Cancer, Non-Small Cell Lung Cancer
Merck Sharp & Dohme LLC
Phase 3
67
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Huizhou, Jiangmen, Liuzhou
2024-11-21
Recruiting
Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
NCT07433283Tumor, Solid, Lung Cancer, Pancreas Cancer, Thyroid Cancer
Sichuan Enray Pharmaceutical Sciences Company
Phase 1/2
54
Beijing, Hunan, Chongqing, Fuzhou, Haikou, Heilongjiang, Shanghai, Chengdu
2024-11-12
Recruiting
Ablation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma
NCT06644430Advanced Hepatocellular Carcinoma, Lung Cancer, Oligometastasis, Ablation
Sun Yat-sen University
Observational
470
Beijing
2024-10-04
Recruiting
TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer
NCT06538012Lung Cancer, Lung Cancer Metastatic, Lung Cancer, Non-small Cell, Lung Cancer Recurrent
Essen Biotech
Phase 1/2
85
Beijing
2024-08-20
Recruiting
Differentiation of Benign and Malignant Pulmonary Nodules by Volatile Organic Compounds in Human Exhaled Breath
NCT06518655Pulmonary Nodules, Multiple, Pulmonary Nodules, Solitary, Lung Cancer
ChromX Health
Observational
3,000
Beijing, Foshan, Guangzhou, Wuhan, Shanghai, Chengdu
2024-06-30
Active, closed
To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations
NCT06194448Lung Cancer
AstraZeneca
Phase 2
76
Beijing, Changsha, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanning
2024-04-21
Recruiting
Real-world Clinical Outcomes of Patients With Early-stage Lung Cancer After the Surgery
NCT06483698Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
20,000
Beijing
2024-03-01
Recruiting
COVID-19 Vaccine Effectiveness Against Recurrent Infection Among Lung Cancer Patients and Biomarker Research
NCT06168032COVID-19 Recurrent, Lung Cancer, Vaccination, Antibody
Peking Union Medical College Hospital
Not applicable
1,224
Beijing
2023-12-08
Recruiting
LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer
NCT05886439Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1/2
60
Beijing
2023-05-11
Recruiting
Research on Early Screening and Diagnosis of Pulmonary Nodules Based on Novel Non-invasive Technologies.
NCT07370077Lung Cancer
Chen KeZhong
Observational
1,800
Beijing
2022-12-31
Active, closed
Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC
NCT05374603Lung Cancer
AstraZeneca
Phase 2
47
Beijing, Changsha, Chongqing, Hangzhou, Jinan, Kunming, Nanchang, Ningbo
2022-11-15
Recruiting
Intraoperative Blood Pressure Management and Dexamethasone in Lung Cancer Surgery
NCT04209218Lung Cancer, Surgery, Blood Pressure Management, Dexamethasone
Peking University First Hospital
Not applicable
1,988
Beijing
2020-04-07
Recruiting
Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers
NCT06255197Lung Cancer, Lung Adenocarcinoma, Lung Squamous Cell Carcinoma, Non Small Cell Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
60,000
Beijing
2019-11-04
Recruiting
Development and Application of a Thrombosis Risk Prediction Model in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors
NCT06950697Lung Cancer, Venous Thromboembolism, Arterial Thromboembolism, Immune Checkpoint Inhibitors (ICIs)
Beijing Chao Yang Hospital
Observational
2,400
Zhengzhou, Hohhot, Beijing
2019-01-01
Rows per page Showing 1–24 of 24
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/beijing

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 24 of those studies with a site in Beijing that also match the filters currently applied.

How many clinical trials are recruiting in Beijing?

19 of the 24 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 1 have not yet opened recruitment, 3 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Beijing), 24 studies
PhaseStudiesRecruitingShare
Observational10941.7%
Phase 25320.8%
Not applicable4316.7%
Phase 1/24416.7%
Phase 3104.2%

Most active sponsors

Lead sponsors with the most studies (Beijing)
Lead sponsorStudiesRecruiting
AstraZeneca53
Cancer Institute and Hospital, Chinese Academy of Medical Sciences33
3H Pharmaceuticals Co., Ltd.11
Beijing Chao Yang Hospital11
Chen KeZhong11
China-Japan Friendship Hospital11
ChromX Health11
Essen Biotech11
Jinghui Wang11
Merck Sharp & Dohme LLC10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.